Todos Medical Stories Day 14 Replace from Ongoing 30-Day Case Research of Paxlovid Rebound Affected person


New York, NY, and Tel Aviv, ISRAEL, Could 06, 2022 (GLOBE NEWSWIRE) — through NewMediaWire — Todos Medical, Ltd. (OTCQB: TOMDF), a complete medical diagnostics and associated options firm, in the present day introduced that its majority-owned subsidiary 3CL Pharma, Ltd. reported a Day 14 replace. The replace is from an ongoing 30-day case examine by Dr. Lee Morgentaler of a 3CL protease cleanse with Tollovid, a 3CL protease inhibitor dietary complement, in a affected person who skilled COVID Rebound following intervention with Pfizer’s Paxlovid.

in article 1


COVID-19 and Acute Sequelae of SARS-CoV-2 (PASC), or Lengthy COVID, are main public well being issues. Rising proof suggests the PASC, for a lot of, might in reality be on account of persistent SARS-CoV-2 an infection that is ready to evade vaccine or infection-induced immunity and trigger recurring and chronic signs. PASC doesn’t seem to guard in opposition to new acute SARS-CoV-2 an infection, and PASC might in reality contribute to poor outcomes in new acute infections and/or recurrent signs from prior an infection. We report a case of a affected person with a historical past of a number of SARS-CoV-2 infections and chronic PASC, who obtained the therapeutic intervention Paxlovid following a optimistic PCR take a look at and skilled extreme rebound of signs beginning on Day 5, the ultimate day of Paxlovid remedy. The affected person’s signs had been resolved following an preliminary 14-day cleanse with 3CL protease inhibitor immune assist dietary complement Tollovid®.


A 53-year-old feminine in wonderful bodily situation skilled 4 COVID-19 infections over the course of two years between March 13, 2020 by way of April 20, 2022.  The affected person is a single mom with a son in school and lived a really reclusive life-style.  Her present blood panels recommend that she is now immunocompromised.  Earlier than the primary COVID-19 an infection on March 13, 2020 the affected person did 3 to six miles of every day path operating 4 occasions per week.  She additionally taught faculty 3 times per week and cycled the 8-mile distance to work every time.  She was 5 ft 6 in, 160 lb, had a resting pulse charge of 60, and had all blood work inside regular limits.  On the time instantly previous to starting intervention with Tollovid on this case examine she weighed 185 lb, her blood work was irregular, and she or he was experiencing imaginative and prescient issues and gastrointestinal points that resulted within the removing of her gall bladder.  From March 13, 2020 to April 20, 2022 she skilled 13 journeys to the Emergency Room.

In March 2020, after isolation for every week the affected person introduced COVID-19 signs of elevated coronary heart charge, shortness of breath, GI tract points, problem respiration, and what the affected person describes as debilitating physique spasms.  These signs had been so extreme that the affected person needed to be transported to the hospital by ambulance. 

In Could 2020, after experiencing worsening signs the affected person checked into Rust Medical Heart in Rio Rancho with excruciating stomach ache.  A cholecystectomy was carried out on an emergency foundation.  The GI signs subsided after surgical procedure.  Throughout that hospital keep she examined destructive on a nasal PCR take a look at. 

A fecal COVID take a look at was accomplished in July 2020.  The primary fecal take a look at was destructive for COVID however the affected person was not having any symptomatic points associated to the GI tract. The affected person remained in full isolation for the following couple of weeks after which had a GI flare up when the second take a look at was accomplished.  This fecal COVID take a look at was COVID-19 optimistic.  The affected person ultimately recovered and returned baseline and was capable of run as much as six miles once more.  

In February 2021, the affected person obtained the primary in a sequence of two Pfizer vaccination photographs.  The affected person tolerated the vaccinations with none uncomfortable side effects.

The following an infection occurred in June 2021 shortly after the affected person broke a 4-month lengthy isolation.  The affected person broke isolation to satisfy vacationers who had been solely sporting fabric masks for cover whereas driving an hour within the automobile.  The affected person began displaying signs inside 2 days after potential publicity.  These signs included elevated coronary heart charge, fever as much as 101, ache within the chest, insomnia, swollen veins, lack of urge for food, purple eyes, trembling, pulse oximeter studying of 93% to 94%, and diarrhea.  She took over-the-counter electrolytes, vitamin C&D, iron dietary supplements, and resveratrol.  Restoration took 3 weeks and the affected person was capable of resume lengthy walks and her temperature normalized. 

Regardless of the affected person’s diligence in practising self-isolation, thereafter she was uncovered to an individual who took off their masks.  On the time the affected person was sporting a fabric masks.  Inside two days of the publicity the affected person was contaminated for the third time and remained sick for at the least a month.  The affected person examined COVID-19 optimistic on August 24, 2021 by a lateral stream antigen take a look at.  The signs manifested extra in her eyes, nasal passage, and auditory system.  Signs included ringing within the ears and double imaginative and prescient.

On December 15, 2021, the affected person eliminated her P100 masks and hermetic goggles throughout a medical examination after which introduced signs of COVID-19 inside 3 days.  The affected person examined COVID-19 optimistic through fast antigen take a look at on December 18, 2021.  The affected person exhibited indicators of Lengthy COVID which embody fever, tremors, complications, diarrhea, and shortness of breath. These signs continued to persist till April 8, 2022.

On April 1, 2022, the affected person began taking prednisone to deal with her purple swollen palms, vasculitis, and straightforward bruising.  On April 8, 2022, the affected person began displaying indicators of COVID and took a PCR fast take a look at which confirmed a faint optimistic studying.  On April 14th, her physician prescribed a 5-day course of Paxlovid.  Inside hours the affected person was symptom free.  She was capable of clear the home and felt so properly she went on a four-mile hike. She additionally seen that this was the primary time she was capable of sleep by way of the night time in two years.  The affected person additionally did voiceovers, and her voice got here again briefly throughout this era.  On the fifth day of Paxlovid remedy she noticed a return of her signs.  She turned bedridden on day 5 with shaking, tremors, 101 fever, and claylike feces.  On April nineteenth the affected person nonetheless examined COVID-19 optimistic. 

On April 21, 2022, the affected person began a routine of Tollovid.  She took three capsules 4 occasions a day for 14 days. Her signs started to resolve inside 24 hours and continued to enhance for ten days.  The affected person is awaiting outcomes of a whole blood panel.  Nonetheless, on Could 4, 2022, she examined COVID-19 destructive through NP/OP swab resulted on rtPCR.  Moreover, a C-Go neutralizing antibody take a look at was carried out indicating 94.731% inhibition with titers larger than 6000 u/ml.  The affected person reported that as of three days in the past all her signs had been resolved.  She attributes this restoration to the remedy with Tollovid. The affected person plans on persevering with to take two capsules of Tollovid twice a day for the following 14 days. 


This case examine reveals that the affected person responded to 3CL protease inhibitors Paxlovid and Tollovid.  Tollovid acted as a wonderful rescue agent for Paxlovid failure in Lengthy COVID or COVID-19.  The affected person noticed reduction in hours utilizing each remedies.  The affected person was totally vaccinated and it didn’t forestall an infection. 

About Tollovid® and Tollovid Each day™

Tollovid and Tollovid Each day are dietary complement merchandise constructed from pure elements that assist assist and keep wholesome immune perform and still have potent 3CL protease inhibition properties primarily based upon in vitro practical assays that present sturdy inhibition of 3CL protease exercise. Tollovid’s 3CL protease IC50 binding affinity is at the least ten occasions (10x) as sturdy as Ivermectin’s revealed 3CL protease IC50 binding affinity. Tollovid Each day’s 3CL protease IC50 binding affinity is at the least two and a half occasions (2.5x) as Ivermectin. Tollovid and Tollovid Each day bind to the lively web site (receptor binding area) of the 3CL protease. Tollovid has a 5-day dosing routine, with 4 doses of three drugs taken every day that gives most immune assist. Tollovid Each day is a every day immune assist product with a dosing routine of twice every day.

About Tollovir®

Tollovir® is a 3CL protease inhibitor and anti-cytokine therapeutic candidate for the remedy of the nidovirus subcategory of coronaviruses that features SARS-CoV-2, COVID-19, SARS-CoV-1, MERS and 229E. Tollovir is constructed from all pure elements which are certified to make sure sturdy inhibition of the 3CL protease in vitro, in addition to sturdy anti-cytokine exercise. Tollovir has efficiently accomplished a Section 2 scientific trial in Israel for the remedy of sufferers hospitalized with COVID-19. Tollovir shall be developed for the remedy of hospitalized COVID-19 (extreme and important), reasonable COVID-19, long-haul COVID and probably pediatric COVID-19. Todos has licensed rights for Tollovir to T-Cell Shield Hellas S.A. for the Greek market.

About Todos Medical Ltd.

Based in Rehovot, Israel with places of work in New York Metropolis, Todos Medical Ltd. (OTCQB: TOMDF) engineers’ life-saving diagnostic options for the early detection of quite a lot of cancers. The Firm’s state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening expertise utilizing peripheral blood evaluation that deploys deep examination into most cancers’s affect on the immune system, in search of biochemical adjustments in blood mononuclear cells and plasma. Todos’ two internally developed cancer-screening checks, TMB-1 and TMB-2 have obtained a CE mark in Europe. Todos not too long ago acquired U.S.-based medical diagnostics firm Provista Diagnostics, Inc. to achieve rights to its Alpharetta, Georgia-based CLIA/CAP licensed lab at the moment performing PCR COVID testing and Provista’s proprietary commercial-stage Videssa® breast most cancers blood take a look at.

Todos can also be creating blood checks for the early detection of neurodegenerative problems, resembling Alzheimer’s illness. The Lymphocyte Proliferation Take a look at (LymPro Take a look at™) is a diagnostic blood take a look at that determines the power of peripheral blood lymphocytes (PBLs) and monocytes to resist an exogenous mitogenic stimulation that induces them to enter the cell cycle. It’s believed that sure illnesses, most notably Alzheimer’s illness, are the results of compromised mobile equipment that results in aberrant cell cycle re-entry by neurons, which then results in apoptosis. LymPro is exclusive in using peripheral blood lymphocytes as a surrogate for neuronal cell perform, suggesting a standard relationship between PBLs and neurons within the mind.

Todos has entered into distribution agreements with corporations to distribute sure novel coronavirus (COVID-19) take a look at kits. The agreements cowl a number of worldwide suppliers of PCR testing kits and associated supplies and provides, in addition to antibody testing kits from a number of producers after finishing validation of mentioned testing kits and provides in its associate CLIA/CAP licensed laboratory in the USA. Moreover, Todos has entered right into a three way partnership with NLC Pharma to pursue the event of diagnostic checks focusing on the 3CL protease, in addition to 3CL protease inhibitors that focus on a elementary reproductive mechanism of coronaviruses.

For extra data, please go to

Ahead-looking Statements

Sure statements contained on this press launch might represent forward-looking statements. For instance, forward-looking statements are used when discussing our anticipated scientific growth packages and scientific trials. These forward-looking statements are primarily based solely on present expectations of administration, and are topic to important dangers and uncertainties that would trigger precise outcomes to vary materially from these described within the forward-looking statements, together with the dangers and uncertainties associated to the progress, timing, value, and outcomes of scientific trials and product growth packages; difficulties or delays in acquiring regulatory approval or patent safety for product candidates; competitors from different biotechnology corporations; and our means to acquire extra funding required to conduct our analysis, growth and commercialization actions. As well as, the next components, amongst others, may trigger precise outcomes to vary materially from these described within the forward-looking statements: adjustments in expertise and market necessities; delays or obstacles in launching our scientific trials; adjustments in laws; lack of ability to well timed develop and introduce new applied sciences, merchandise and functions; lack of validation of our expertise as we progress additional and lack of acceptance of our strategies by the scientific neighborhood; lack of ability to retain or appeal to key workers whose data is important to the event of our merchandise; unexpected scientific difficulties which will develop with our course of; larger value of ultimate product than anticipated; lack of market share and stress on pricing ensuing from the competitors; and laboratory outcomes that don’t translate to equally good leads to actual settings, all of which may trigger the precise outcomes or efficiency to vary materially from these contemplated in such forward-looking statements. Besides as in any other case required by regulation, Todos Medical doesn’t undertake any obligation to publicly launch any revisions to those forward-looking statements to mirror occasions or circumstances after the date hereof or to mirror the incidence of unanticipated occasions. For a extra detailed description of the dangers and uncertainties affecting Todos Medical, please discuss with its studies filed now and again with the U.S. Securities and Change Fee.

Todos Company Contact:

Daniel Hirsch


Todos Medical

917-983-4229 x 104

[email protected]

Todos Investor Relations Contact:

Eric Ribner

LifeSci Advisors

Electronic mail: [email protected]

The content material is by GlobeNewswire. DKODING Media isn’t chargeable for the content material supplied or any hyperlinks associated to this content material. DKODING Media isn’t chargeable for the correctness, topicality or the standard of the content material.


Please enter your comment!
Please enter your name here